TRENDLINES GROUP, an Israeli company focused on developing technology-based companies in the medical and agricultural fields, has lodged its preliminary offer document for a listing on the Catalist board of the Singapore Exchange.
Trendlines said it has entered into a cornerstone subscription agreement with B. BRAUN Melsungen AG, one of the world´s leading healthcare suppliers with global sales of healthcare products of EUR 5.43 billion.
B. BRAUN will subscribe for S$7.1 million worth of Trendlines’ shares.
In addition, Trendlines has entered into a non-legally binding memorandum of understanding with B. BRAUN for the purpose of establishing mutual deal flow, identifying potential new investments, cooperating in the establishment of accelerators and incubators in selected markets worldwide, and collaborating on the development of new technologies, solutions and products in medical fields.
Mr. D. Todd Dollinger, Co-Chairman and CEO of Trendlines, said, “Trendlines views Singapore and the region as places of extraordinary opportunity. Employing Trendlines’ expertise in establishing companies and developing them through investment and comprehensive support, we are well-positioned to partner with local inventors, entrepreneurs and multinational corporations.”
Steve Rhodes, Co-Chairman and CEO of Trendlines, added, “Listing on SGX-ST not only provides us a gateway to capital facilitating future investments, but also an enhanced platform for business opportunities and strategic partnerships in Singapore and the region. We look forward to completing our Proposed Listing and the establishment of our first incubator in Singapore.”
Trendlines operates primarily through its two subsidiaries, Trendlines Medical and Trendlines Agtech, and its own internal innovation centre, Trendlines Labs, all of which are based in Israel.
To fulfill its mission of “creating and developing companies to improve the human condition”, Trendlines discovers, invests in, incubates and provides services to life sciences companies in the fields of medical and agricultural technologies.
Since commencing operations in September 2007, Trendlines has established and incubated 60 portfolio companies, 17 of which are now at the “commercialisation stage” and are generating revenues.
Five portfolio companies have been acquired by, or sold their assets to, multinational corporations and two portfolio companies, FlowSense and E.T.View, each completed a public listing transaction on the Tel-Aviv Stock Exchange in 2010.
FlowSense Medical Ltd. (together with its wholly owned subsidiary, FlowSense) was subsequently acquired by a multinational corporation and delisted from the TASE while E.T.View Medical continues to be listed on the TASE (with E.T.View as its wholly owned principal operating subsidiary).